Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Accessing medicines
›
One Wales Medicines process
›
One Wales medicine assessment documents
›
OW12 documents
OW12 documents
12/07/2024
First review of reassessment: rituximab (OW12) One Wales Interim Decision and review report Jun 24
12/07/2024
Reassessment (to include 1st line use): rituximab (OW12) One Wales Interim Decision Apr 23
12/07/2024
Reassessment (to include 1st line use): rituximab (OW12) Evidence Status Report Mar 23
12/07/2024
Second review: rituximab (OW12) One Wales Interim Decision and review report Dec 21
12/07/2024
First review: rituximab (OW12) One Wales Interim Decision and review report Nov 20
12/07/2024
Original assessment: Rituximab (OW12) One Wales Interim Decision Aug 19
12/07/2024
Original assessment (4th line use and later): Rituximab (OW12) Evidence Status Report Apr 19
Follow AWTTC:
